Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31601400 | 1.00 | ALDH1A1 (0.49) | ALDH1A1MEN1KMT2APOLBHPGD | |
| SCHEMBL502093 | 1.00 | ALDH1A1 (0.49) | ALDH1A1MEN1KMT2APOLBHPGD | |
| SCHEMBL18497906 | 0.84 | MAPT (0.42) | ALDH1A1POLBCYP1A2MAPTACHE | |
| SCHEMBL18501652 | 0.84 | MAPT (0.42) | ALDH1A1POLBCYP1A2MAPTACHE | |
| SCHEMBL17754960 | 0.84 | RAB9A (0.51) | ALDH1A1MEN1KMT2AMAPTRAB9A | |
| SCHEMBL13140497 | 0.84 | ESR1 (0.48) | ALDH1A1HPGDMAPTRAB9AACHE | |
| SCHEMBL14567176 | 0.84 | ESR1 (0.48) | ALDH1A1HPGDMAPTRAB9AACHE | |
| SCHEMBL2881396 | 0.84 | ESR1 (0.48) | ALDH1A1HPGDMAPTRAB9AACHE | |
| SCHEMBL38660016 | 0.84 | MEN1 (0.49) | ALDH1A1MEN1KMT2APOLBHPGD | |
| SCHEMBL17875268 | 0.84 | ACHE (0.61) | ALDH1A1MEN1KMT2AHPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025111464-A1 | JAK2 V617F INHIBITORS AND METHODS OF USE THEREOF | RAYTHERA, INC. (US) | 2025-05-30 | — | — | WO | disclosed |
| CN-110662741-B | 3-methyl-pyrrolidine-2, 5-dione derivatives useful as CGRP receptor antagonists | 伊莱利利公司 | 2022-08-16 | — | — | CN | disclosed |
| CN-110678457-B | CGRP receptor antagonists | 伊莱利利公司 | 2022-08-16 | — | — | CN | disclosed |
| US-11066386-B2 | CGRP receptor antagonists | ELI LILLY AND COMPANY (US) | 2021-07-20 | — | — | US | disclosed |
| EP-3625220-B1 | CGRP RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2021-03-10 | — | — | EP | disclosed |
| EP-3625221-B1 | 3-METHYL-PYRROLIDINE-2,5-DIONE DERIVATIVES USEFUL AS CGRP RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2021-03-03 | — | — | EP | disclosed |
| CN-107922385-B | CGRP receptor antagonists | 伊莱利利公司 | 2020-09-08 | — | — | CN | disclosed |
| US-20200181111-A1 | CGRP RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2020-06-11 | — | — | US | disclosed |
| CN-110678457-A | CGRP receptor antagonists | 伊莱利利公司 | 2020-01-10 | — | — | CN | disclosed |
| CN-110662741-A | 3-methyl-pyrrolidine-2, 5-dione derivatives useful as CGRP receptor antagonists | 伊莱利利公司 | 2020-01-07 | — | — | CN | disclosed |
| US-10336726-B2 | 3-methyl-pyrrolidine-2,5-dione derivatives useful as CGRP receptor antagonists | ELI LILLY AND COMPANY (US) | 2019-07-02 | — | — | US | disclosed |
| CN-107922385-A | Cgrp receptor antagonists | 伊莱利利公司 | 2018-04-17 | — | — | CN | disclosed |
| US-9708297-B2 | CGRP receptor antagonists | ELI LILLY AND COMPANY (US) | 2017-07-18 | — | — | US | disclosed |
| US-9708297-B2 | CGRP receptor antagonists | ELI LILLY AND COMPANY (US) | 2017-07-18 | — | — | US | disclosed |
| US-20170044138-A1 | CGRP RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2017-02-16 | — | — | US | disclosed |
| US-20170044138-A1 | CGRP RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200181111-A1 | CGRP RECEPTOR ANTAGONISTS | CALCRL, CALCR, CCKBR | ALDH1A1 1398/4885MEN1 1821/4885KMT2A 4375/4885 |
| US-11066386-B2 | CGRP receptor antagonists | CALCRL, CALCR, CCKBR | ALDH1A1 1398/4885MEN1 1821/4885KMT2A 4375/4885 |
| US-10336726-B2 | 3-methyl-pyrrolidine-2,5-dione derivatives useful as CGRP receptor antagonists | CALCR, CALCRL, GRPR | ALDH1A1 1695/4885MEN1 1530/4885KMT2A 2916/4885 |
| US-20170044138-A1 | CGRP RECEPTOR ANTAGONISTS | CALCRL, CALCR, CCKBR | ALDH1A1 1467/4885MEN1 1975/4885KMT2A 3881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.